Crunch time for GlaxoSmithKline’s big heart drug bet

November 11, 2013 4:05 PM

29 0

LONDON (Reuters) – Cardiologists and shareholders in GlaxoSmithKline are about to learn if a big gamble on a new kind of heart medicine has paid off, with modest expectations creating a potentially big share price boost if the news is good.

Britain’s biggest drugmaker hopes its once-daily pill darapladib can prevent heart attacks and strokes by fighting clogged arteries in a completely different way from cholesterol-lowering drugs.

Read more

To category page